ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2032

Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis

Olga S. Zhukov1, Rania W. Abolhosn1, Jonnielyn G. Rivera1, Mary Lape Nixon2, Robert J. Lagier3, Harry E. Prince4, Hollis J. Batterman4 and Stanley J. Naides1, 1Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 2Lab Sciences, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA, 3Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 4Lab Services, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Infection, rheumatoid arthritis (RA) and viruses

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Infection-related Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:  Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate to severe polyarthritis that clinically resembles rheumatoid arthritis (RA).1 As the majority of CHIK arthritis patients reportedly lack rheumatoid factor (RF) and cyclic citrullinated peptide antibody (CCP), differential diagnosis includes seronegative RA.2  Extracellular 14-3-3η, a chaperonin, is a novel biomarker for joint damage in rheumatoid arthritis (RA) and erosive psoriatic arthritis, with serum elevation occurring in early RA. We previously demonstrated that 21% of patients with early “seronegative” RA and 67% of patients with established “seronegative” RA are 14-3-3η-positive.3In order to determine the utility of RF, CCP, and 14-3-3η in the differential diagnosis of CHIK arthritis versus RA, we tested CHIK infected patient serum for 14-3-3η.

Methods:  Serum samples were submitted for CHIK IgM and IgG serology. De-identified remnant samples positive for CHIK IgM were tested for 14-3-3η by a proprietary laboratory-developed sandwich ELISA. Rheumatoid factor (RF) isotypes and cyclic citrullinated peptide antibody (CCP) were determined by ELISA.

Results:  Of 234 CHIK IgM-positive sera, 223 were also CHIK IgG-positive (95.3%, CI 91.7% to 97.6%). RF IgM was positive in 51 of the CHIK IgM-positive patients (21.8%, CI 16.7% to 27.6%), RF IgG in 7 (3.0%, CI 1.2% to 6.1%), and RF IgA in 10 (4.3%, CI 2.1% to 7.7%). CCP was positive in only 4 patients (1.7%, CI 0.5% to 4.3%). Two isotypes of RF were present in 7 patients, only one of which was CCP-positive. All 3 RF isotypes were present in 1 patient, but the patient was CCP-negative. At least one isotype of RF was positive in 59 patients (25.2%, CI 19.8% to 31.3%). 14-3-3η was positive in 25 patients (10.7%, CI 7.0% to 15.4%). Of those 25, RF was positive in only 6 (24.0%, CI 9.4% to 45.1%) and CCP was positive in only 2 (8.0%, CI 1.0% to 26.0%).

Conclusion:  Nearly all patients were positive for CHIK IgG at the time of diagnosis based on a positive CHIK IgM. At least one RF isotype was present in 25.2% of patients. CCP was uncommon. 14-3-3η was present in only 10.7% in contrast to a 64% positivity rate in early RA patients.4  Therefore, RF may not be helpful in differentiating early RA from CHIK arthritis. However, CCP and 14-3-3η occur less frequently in CHIK arthritis and when present may aid in the differential diagnosis of RA from CHIK arthritis.

References: 1. Arroyo-Avila, Vilá. P R Health Sci J. 34:71-77, 2015; 2. Miner et al. Arth Rheum 67:1214-20, 2015; 3. Naides, Marotta. J Rheum, in press; 4.. Maksymowych, et al. J Rheum. 41:2104-13, 2014.


Disclosure: O. S. Zhukov, Quest Diagnostics, 3; R. W. Abolhosn, Quest Diagnostics, 3; J. G. Rivera, Quest Diagnostics, 3; M. Lape Nixon, Quest Diagnostics, 3; R. J. Lagier, Quest Diagnostics, 3; H. E. Prince, Quest Diagnostics, 3; H. J. Batterman, Quest Diagnostics, 3; S. J. Naides, Quest Diagnostics, 3.

To cite this abstract in AMA style:

Zhukov OS, Abolhosn RW, Rivera JG, Lape Nixon M, Lagier RJ, Prince HE, Batterman HJ, Naides SJ. Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/chaperonin-protein-14-3-3eta-cyclic-citrullinated-peptide-antibody-and-rheumatoid-factor-in-the-differential-diagnosis-of-chikungunya-arthritis-versus-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chaperonin-protein-14-3-3eta-cyclic-citrullinated-peptide-antibody-and-rheumatoid-factor-in-the-differential-diagnosis-of-chikungunya-arthritis-versus-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology